Erythropoietin

Cytokine (glycoprotein Hormone)Rx: PrescriptionCompound: Approved

Also known as: EPO, Epoetin alfa, Epoetin beta, Epogen, Eprex, NeoRecormon, Procrit, rhEPO

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Source Erythropoietin at Peptiology

Save 10% with code PEPTI-BOSSRABBIT-10

Shop Now & Save 10% →

Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.

Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.

Summary

Erythropoietin (EPO) is a recombinant hematopoietic glycoprotein hormone that stimulates red‑blood‑cell production. It is prescribed to treat anemia, most commonly in chronic kidney disease, and is delivered by injection. Research has explored additional uses such as neuroprotection in newborns with hypoxic‑ischemic encephalopathy, treatment of iron‑deficiency anemia during pregnancy, and its role in the erythropoietic response of heart‑failure patients.

Mechanism of Action

Erythropoietin binds the erythropoietin receptor (EPOR) on erythroid progenitor cells in the bone marrow, activating the JAK2‑STAT5 signaling cascade. This promotes survival, proliferation, and differentiation of these cells into mature red blood cells, increasing hemoglobin and oxygen‑carrying capacity. In disease states, elevated endogenous EPO participates in an axis with erythroferrone, transferrin‑receptor‑1 and hepcidin that regulates iron utilization, a pathway highlighted in heart‑failure studies.

What the Research Shows

Clinical evidence for EPO beyond its approved anemia indication is mixed. A 2024 systematic review and meta‑analysis of seven studies (903 neonates) found no reduction in death, neurodisability, or cerebral palsy after high‑dose EPO for hypoxic‑ischemic encephalopathy, and noted a trend toward more serious adverse events. A parallel 2022 randomized trial of 500 infants reported identical death or neurodevelopmental‑impairment rates between EPO and placebo, with a higher adverse‑event count in the EPO group. In contrast, a 2025 systematic review of five small studies in pregnant women (n≈207) suggested that serial recombinant EPO plus iron supplementation may raise hemoglobin more effectively than iron alone, although heterogeneity prevented meta‑analysis. Heart‑failure research (2025) described an endogenous EPO‑erythroferrone‑TfR1‑hepcidin axis that is amplified by SGLT2‑inhibitor therapy, underscoring EPO’s role in iron mobilization rather than testing exogenous EPO.

Reported Benefits

Evidence indicates that recombinant EPO, when administered serially together with iron, can improve hemoglobin levels in pregnant patients with refractory iron‑deficiency anemia, as reported in three of five reviewed studies. Its primary approved benefit remains robust stimulation of erythropoiesis, correcting anemia in conditions such as chronic kidney disease, where it reliably raises red‑cell mass and reduces transfusion needs.

Limitations of the Evidence

High‑quality trials have not demonstrated neuroprotective benefit of EPO in newborns with hypoxic‑ischemic encephalopathy, and one large trial reported more serious adverse events with EPO. The pregnancy literature is limited to small, heterogeneous studies, preventing definitive conclusions. Data on direct therapeutic use in heart failure are observational, describing endogenous pathways rather than exogenous EPO efficacy. Larger, well‑designed trials are needed to clarify these potential indications.

Safety Considerations

In neonatal hypoxic‑ischemic encephalopathy trials, EPO was associated with a modest increase in serious adverse events compared with placebo. No specific adverse‑event types are detailed in the abstracts, but the signal suggests careful monitoring when used off‑label. Established safety concerns for EPO, such as thromboembolic risk, are not addressed in the provided studies, reinforcing the need for vigilance in any non‑approved application.

How It Is Administered

Erythropoietin is supplied as a sterile injectable solution for intravenous or subcutaneous use. Neonatal studies employed 1000 U/kg doses given intravenously at birth and on days 2, 3, 4, and 7. Pregnancy investigations used serial dosing regimens in conjunction with iron supplementation, though exact schedules varied across trials. Commercial formulations are typically stored refrigerated and reconstituted before administration.

Routes of Administration

IntravenousSubcutaneous

Goals & Uses

  • Treatment of anemia in chronic kidney diseaseHematology / NephrologyHigh
  • Neuroprotection (investigational)Neurology / ResearchLow
  • Anemia of chronic kidney diseaseHematologyHigh
  • Treatment of chemotherapy-induced anemiaOncology / HematologyHigh
  • Athletic performance enhancement (illicit)Sports / DopingModerate
  • Chemotherapy‑induced anemiaOncologyHigh
  • Anemia in HIV infectionInfectiousModerate
  • Reduction of allogeneic blood transfusions in surgerySurgery / Perioperative MedicineHigh
  • Treatment of anemia in HIV-infected patients on zidovudineInfectious Disease / HematologyHigh

Contraindications

  • Use to target hemoglobin above 11–12 g/dL in cancer patientsOncologyHigh
  • Hypersensitivity to erythropoietin or excipientsAllergicHigh
  • Thrombotic risk conditions (e.g., recent DVT, PE)HematologicalModerate
  • Pure red cell aplasia (PRCA) due to prior EPO therapyImmunologicalHigh
  • Known hypersensitivity to EPO or any excipientImmunologicHigh
  • Active malignancy not receiving chemotherapyOncologyModerate
  • Uncontrolled hypertensionCardiovascularHigh

Adverse Effects

  • HypertensionCardiovascularCommonHigh blood pressure
  • Injection site reactionsLocalCommon
  • HeadacheNeurologicCommonPain in the head or upper neck
  • Thromboembolic events (DVT, PE, stroke, MI)Cardiovascular / HematologicalUncommon
  • Thromboembolic eventsCardiovascularUncommon
  • Flu‑like syndromeSystemicCommon
  • Tumor progression or recurrenceOncologicalUnknown
  • Pure red cell aplasia (PRCA)Immunological / HematologicalRare

Drug Interactions

  • Androgens (e.g., testosterone)Moderate
  • Antihypertensive agentsModerate
  • Iron supplementsLow
  • ACE inhibitorsLow
  • AntihypertensivesModerateMay potentiate hypotensive effects in some contexts
  • Warfarin / anticoagulantsModerate

Population Constraints

  • PregnancyReproductive SafetyRelative
  • Pediatric patientsAgeRelative
  • Patients with cardiovascular disease or recent strokeCardiovascularRelative
  • Cancer patients not on chemotherapyOncologicalAbsolute
  • Pregnant womenReproductiveRelative
  • Pediatric patients (neonates)AgeRelative

Regulatory Status

  • European UnionApprovedApproved: Anemia due to CKD, Chemotherapy‑induced anemiaEMA‑approved; biosimilars available.
  • United StatesApprovedApproved: Anemia due to CKD, Chemotherapy‑induced anemia, HIV‑related anemiaFDA‑approved as Epogen/Procrit.
  • United KingdomApprovedApproved: Anemia due to CKD, Chemotherapy‑induced anemiaMHRA‑approved; same as EU.

Approved as biologic; multiple biosimilar versions exist. Dosing requires monitoring of hemoglobin and blood pressure.

Evidence & Sources

Frequently Asked Questions

What is erythropoietin and how does it work?

Erythropoietin is a recombinant hormone that binds the EPOR on bone‑marrow progenitor cells, triggering JAK2‑STAT5 signaling. This enhances survival, proliferation, and maturation of red‑cell precursors, raising hemoglobin and oxygen delivery.

Does erythropoietin improve outcomes for newborns with hypoxic‑ischemic encephalopathy?

Large randomized trials and meta‑analyses have not shown a reduction in death, neurodisability, or cerebral palsy after high‑dose EPO, and one study noted more serious adverse events in the treated group.

Can erythropoietin help treat anemia during pregnancy?

A systematic review of small studies suggests that serial recombinant EPO combined with iron may raise hemoglobin more effectively than iron alone, but the evidence is limited and heterogeneous.

How is erythropoietin administered?

It is given by injection, either intravenously or subcutaneously. Neonatal protocols used 1000 U/kg IV doses at multiple time points; pregnancy studies used repeated doses alongside iron, with exact schedules varying by trial.

What safety concerns should be considered?

In newborn trials, EPO was linked to a higher rate of serious adverse events. While thrombotic risk is known for EPO, the cited studies do not detail specific events, so careful monitoring is advised when using it off‑label.

What is Erythropoietin used for?

Erythropoietin is educationally associated with: Treatment of anemia in chronic kidney disease, Neuroprotection (investigational), Anemia of chronic kidney disease, Treatment of chemotherapy-induced anemia, Athletic performance enhancement (illicit), Chemotherapy‑induced anemia, Anemia in HIV infection, Reduction of allogeneic blood transfusions in surgery, Treatment of anemia in HIV-infected patients on zidovudine. Educational only — not medical advice.

How is Erythropoietin administered?

Recorded routes of administration: Intravenous, Subcutaneous.

What are the potential side effects of Erythropoietin?

Reported adverse effects include: Hypertension, Injection site reactions, Headache, Thromboembolic events (DVT, PE, stroke, MI), Thromboembolic events, Flu‑like syndrome, Tumor progression or recurrence, Pure red cell aplasia (PRCA). This list is not exhaustive — consult a qualified clinician.

Who should avoid Erythropoietin?

Recorded contraindications: Use to target hemoglobin above 11–12 g/dL in cancer patients, Hypersensitivity to erythropoietin or excipients, Thrombotic risk conditions (e.g., recent DVT, PE), Pure red cell aplasia (PRCA) due to prior EPO therapy, Known hypersensitivity to EPO or any excipient, Active malignancy not receiving chemotherapy, Uncontrolled hypertension. Consult a qualified clinician before use.

More Cytokines and Chemokines

See all Cytokines and Chemokines →

Browse All PeptidesBuild My Stack